Evaluation of the effectiveness of Biejia-Ruangan compound on liver fibrosis in non-alcoholic fatty liver disease

LYU Guiji; CHEN Chun; HE Mengwen; BAI Zhaofang; JI Dong

doi:10.3969/j.issn.1007-8134.2024.01.001

Abstract：Objective To evaluate the therapeutic effectiveness of biejia-ruangan compound ( BRC ) in liver fibrosis caused by non-alcoholic fatty liver disease ( NAFLD ). Methods The clinical data of 144 patients in the Fifth medical center of PLA general hospital from January 2018 to February 2023 were retrospectively enrolled. According to the treatment, 76 patients were divided into only liver protection treatment ( control group ) and 68 patients were divided into the liver protection treatment combining BRC ( treatment group ). The effectiveness was evaluated based on the improvement rate of liver fibrosis after 6-month treatment, which was defiend as ≥20％ reduction in fibrosis-4 score ( FIB-4 ), aspartate aminotransferase to platelet ratio index ( APRI ), or liver stiffness measurement ( LSM ). Multivariate analysis was conducted to explore BRC treatment associated with the effectiveness of NAFLD. Results The improvement rates of FIB-4, APRI and LSM in treatment group were 75.6％, 69.9％ and 88.6％, respectively, which were significantly higher than the control group ( 24.4％, 30.1％ and 11.4％, P<0.05 ). The level of total cholesterol ( TC ) was lower after treatment ( P=0.009 ), while there was no significant change in control group ( P >0.05 ). The level of triglycerides ( TG ) showed no statistical change in two groups before and after treatment ( P >0.05 ). The logistic regression analysis showed that BRC treatment was a protective factor for liver fibrosis, indicating effectiveness of BRC in NAFLD with liver fibrosis. Conclusion BRC could significantly improve the liver fibrosis in NAFLD.